Inhibrx to present ordastobart plus pembrolizumab Phase 2/3 HexAgon — HN data at ESMO Congress

Inhibrx will present Phase 2/3 HexAgon-HN primary analysis for ordastobart (INBRX-106) plus pembrolizumab at ESMO on Oct. 25, 2026. Secondary efficacy data from the Phase 2 ChonDRAgon study of ozekibart (INBRX-109) in conventional chondrosarcoma will be presented Oct. 29, 2026 at MSTS. Updated subgroup and progression-free survival results for INBRX-109 in chondrosarcoma are scheduled for CTOS on Nov. 20, 2026. CTOS will also feature a poster on Nov. 19, 2026 on INBRX-109 combined with irinotecan and temozolomide in Ewing sarcoma. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibrx Biosciences Inc. published the original content used to generate this news brief via (Ref. ID: 202610131600PR_NEWS_USPR_____LA71319) on October 13, 2026, and is solely responsible for the information contained therein. (C)